GENE ONLINE|News &
Opinion
Blog

.

Зеркало официального сайта всегда доступно для входа на Мостбет, даже при ограничениях. Скачать Mostbet – это шаг к удобству и азартным развлечениям.

Если вы ищете место для увлекательных ставок, обратите внимание на Joycasino, где лучшие предложения для игроков ждут вас.
2021-10-05| Licensing

Xencor and Janssen Join Forces Against B-cell Lymphoma in a New Billion-Dollar Deal

by Daniel Ojeda
Share To

Activating T-cells is an effective approach to target some types of cancers. However, regulating this activation is crucial. For example, a Phase 1 clinical testing of an anti-CD28 antibody resulted in life-threatening adverse effects.

With a new collaboration, Janssen and Xencor aim to develop CD28 antibodies that selectively activate T-cells to attack B-cell lymphoma cancer cells. The deal could potentially be worth more than a billion dollars. Xencor’s stock jumped almost 5.5% following the news.

Xencor’s proprietary XmAb antibody engineering platform allows them to modify the Fc domain of an antibody. This is the region that determines the immune function of an antibody. This will enable Xencor to regulate the cytotoxic, bispecific, and inhibitory activity of antibodies as well as extend their half-life.

Their platform has successfully produced 9 therapeutic candidates that are currently in clinical trials for a variety of oncology targets and autoimmune diseases. Their three most advanced products, currently in Phase 2 or Phase 1B/2 clinical trials, are:

  • Vudalimab, a bispecific antibody that targets PD-1 and CTLA-4, for the treatment of Metastatic Castration-Resistant Prostate Cancer (mCRPC).
  • Tidutamab, an antibody targeting SSTR2 and CD3, is currently in Phase 1B/2 for the treatment of Merkel cell carcinoma.
  • Obexelimab, a CD19 antibody, for the treatment of Lupus.
Related Article: Bispecific Antibodies or CAR T-Cells: Which One of These Cancer Immunotherapies Would Prevail?

 

A Billion-Dollar Deal

1) The development and commercialization of Plamotamab, one of Xencor’s antibodies currently Phase 1 clinical trials for the treatment of B-cell tumors, and 

2) The development of novel antibodies targeting B-cells by activating T-cells via the CD28 receptor.

As part of the deal, Janssen will receive worldwide rights for development and commercialization to Plamotamab. Clinical development costs will be shared between both companies on an 80/20 basis, with Janssen covering 80% of the cost. One exception to this cost-sharing agreement is the ongoing clinical trial testing of the combination of plamotamab, tafasitamab, and lenalidomide in patients with B-cell lymphoma. The Phase 2 trial for this collaboration is expected to begin in late 2021 or early 2022.

Additionally, Xencor will develop CD28 bispecific antibody candidates against B-cell targets. Janssen will have exclusive worldwide rights for select molecules. 

In return, Xencor could receive up to 1.313 billion, including $100 million upfront and an additional $25 million in newly issued shares purchased by Johnson & Johnson Innovation. The rest will be contingent on development, regulatory, and sale milestone payments. On top of this, Xencor will also receive royalties ranging from mid-teens to low-twenties.

“The treatment landscape in B-cell lymphoma will potentially be redefined by CD20 x CD3 bispecific antibodies, such as Plamotamab, and the best outcomes for patients will require creative combination approaches using complementary mechanisms of action. We are delighted to collaborate with Janssen’s leading scientists to expand the scope of the Plamotamab program, particularly as we explore opportunities to combine with novel B-cell targeted CD28 bispecific antibodies that can potentially selectively enhance T-cell cytotoxic activity,” said Bassil Dahiyat, Ph.D., President, and CEO at Xencor.

©www.geneonline.com All rights reserved. Collaborate with us: [email protected]
Related Post
JPM 2025 Looks at the Cell and Gene Therapy Landscape – Autoimmune, Cancer, and Chronic Diseases are Front and Center
2025-01-21
Cecile Richards’s Battle with Glioblastoma
2025-01-21
Neuro, Pain, and Cancer Top the List at JPM 2025 Healthcare Conference
2025-01-17
LATEST
Novo Nordisk Bets Big on CagriSema With A Heavyweight Move Planned for 2026
2025-02-07
Major Win – FDA Grants Fast Track Designation to Adicet Bio’s ADI-001 for Lupus Disease
2025-02-07
First-of-its-Kind Diagnostic Aid Uses a Single Hair Strand to Detect Autism Risk in Babies
2025-02-06
Teladoc Dials Up Virtual Care with $70 Million Acquisition of Catapult
2025-02-06
Silicon Valley in the Crosshairs as EU Readies to Strike U.S. Big Tech
2025-02-06
Johnson & Johnson Under Fire Again as Legal Action Over Alleged Talc-Cancer Link Moves to the UK
2025-02-05
MediBuddy Partners with Japan’s ELECOM to Launch Smart Health IoT Devices in India
2025-02-05
EVENT
2025-02-05
Precision Medicine World Conference 2025
Santa Clara, California
2025-02-19
Healthcare Conference Taipei 2025
Taipei, Taiwan
2025-03-17
BIO-Europe Spring 2025
Milan, Italy
2025-04-21
World Vaccine Congress 2025
Washington, U.S.A
2025-04-25
AACR Annual Meeting 2025
Chicago, U.S.A
Scroll to Top